October 29, 2015.
The United States Department of Justice (DOJ) announced today that Warner Chilcott has agreed to plead guilty to healthcare fraud and pay $125 million to resolve civil and criminal liability arising from the illegal promotion of the drugs Actonel, Asacol, Atelvia, Doryx, Enablex, Estrace, and Loestrin, and various formulations of these drugs. According to DOJ, the company's marketing scheme involved paying kickbacks to health care professionals to prescribe its drugs as well as filling out and submitting fraudulent prior authorization requests to evade Medicare and Medicaid formulary restrictions, also a violation of patients' privacy protections under HIPAA. DOJ also today announced the indictments of former company president Carl Reichel and district managers Timothy Garcia and Landon Eckles. On Tuesday, DOJ filed an indictment against Rita Luthra, a Massachusetts physician. Last July, district manager Jeffrey Podolosky also pled guilty. The civil settlement resolves a lawsuit filed under the whistleblower provisions of the False Claims Act, which permit private individuals to sue on behalf of the government for false claims and to share in any recovery. The Simmer Law Group, Seeger Weiss and MoloLamken represented the two whistleblowers in the case.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.